New nanoparticle therapy tested for autoimmune liver disease – first human trial complete
Disease control
Completed
This first-in-human study tested a single dose of PVT201, a nanoparticle-based drug, in 24 people: healthy volunteers and patients with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC). The main goal was to check safety and how the drug moves through the …
Phase: PHASE1 • Sponsor: Parvus Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC